መነሻ › ሙያዎች › Medical Scientists, Except Epidemiologists › Lexington, MA
Medical Scientists, Except Epidemiologists በLexington፣ MA፡ የH-1B ደመወዞች
37 የሥራ ሁኔታ ማመልከቻዎች ለዚህ ሙያ ከሥራ ቦታ ጋር በLexington፣ MA። መካከለኛ የቀረበ መሠረታዊ ደመወዝ $141,084፤ መካከለኛ ግማሽ $117,714–$158,945።
ማመልከቻዎች (LCAs)37
መካከለኛ የሚቀርብ ደመወዝ$141,084
የደመወዞች መካከለኛ ግማሽ$117,714–$158,945
ከ10ኛ እስከ 90ኛ ፐርሰንታይል$99,460–$164,480
በደመወዝ ደረጃ
| የደመወዝ ደረጃ | መካከለኛ ደመወዝ |
|---|---|
| ደረጃ I (መግቢያ) | $132,500 |
| ደረጃ II (ብቁ) | $110,000 |
| ደረጃ III (ልምድ ያለው) | $135,462 |
| ደረጃ IV (ሙሉ ብቃት ያለው) | $159,317 |
የሥራ ሚኒስቴር ለእያንዳንዱ ሙያ እና አካባቢ ከደረጃ I (መግቢያ) እስከ ደረጃ IV (ሙሉ በሙሉ ብቁ) ድረስ አራት የሚገባ ደመወዝ ደረጃዎችን ይወስናል። አሠሳሪው ከሥራው መስፈርቶች ጋር የሚስማማውን ደረጃ ይመርጣል።
አሠሪዎች
| አሠሪ | LCAs | መካከለኛ ደመወዝ |
|---|---|---|
| Takeda Development Center Americas, Inc. | 11 | $140,000 |
| SalioGen Therapeutics Inc. | 4 | $99,460 |
| Takeda Pharmaceuticals USA, Inc. | 3 | $150,000 |
| Voyager Therapeutics, Inc. | 3 | $159,771 |
| Cystic Fibrosis Foundation | 3 | $143,000 |
| Keros Therapeutics | 2 | $106,500 |
| Novo Nordisk Research & Development US, Inc. | 2 | $154,942 |
| Takeda Pharmaceuticals America Inc. | 2 | $164,480 |
| General Hospital Corporation | 1 | $110,000 |
| Agenus Inc. | 1 | $110,000 |
| Fosun Pharma USA, Inc. | 1 | $95,400 |
| Curis, Inc. | 1 | $205,000 |
| Dicerna Pharmaceuticals, Inc. | 1 | $150,000 |
| KSQ Therapeutics, Inc. | 1 | $158,882 |
| Bicycle Therapeutics, Inc. | 1 | $135,000 |
የሥራ መደቦች
- Scientist I3
- Scientist3
- Senior Scientist I3
- Senior Research Associate2
- Sr. Staff Engineer CMC2
- Scientist II2
- Medical Science Liaison2
- Researcher1
- Senior Clinical Trials Associate Manager1
- Scientist, In Vivo1
- Translational Medicine Scientist, Clinical Development1
- Associate Scientific Director1
- Scientist CMC1
- Associate Scientist1
- Associate Director Clinical Sciences1
ደመወዞች በእያንዳንዱ ማመልከቻ ላይ በተገለጸው ደመወዝ ዝቅተኛ ጫፍ ሲሆኑ ወደ ዓመታዊ መጠን ተቀይረዋል፤ ስታቲስቲክሶች የተረጋገጡ ሙሉ ጊዜ ማመልከቻዎችን ብቻ ይጠቀማሉ። LCA የቪዛ ማረጋገጫ አይደለም፤ አንድ LCA ለብዙ ቦታዎች ሊሸፍን ይችላል። ምንጭ፡ የአሜሪካ የሥራ ሚኒስቴር፣ OFLC LCA መረጃ ማሳያ መረጃ፣ የፋይናንስ ዓመታት 2023–2026 (የቅርብ ጊዜ ውሳኔ 30 ጁን 2026)።